Novel composition and methods for the treatment of psoriasis

• US 20060182755A1
• Filed: 09/10/2003
• Published: 08/17/2006
• Est. Priority Date: 09/11/2002
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Wood, William I, Schoenfeld, Jill R, Jackman, Janet K, Clark, Hilary, Bodary-Winter, Sarah C., Wu, Thomas D
• Application Number:
  US10/527,101
• Publication Number:
  US 20060182755A1
• Time in Patent Office: Days
• US Class Current: 424/185.100
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 : Expression markers
• CPC Class Codes: G01N 2500/04 : Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2800/205 : Scaling palpular diseases, e.g. psoriasis, pytiriasis
• CPC Class Codes: G01N 33/6893 : related to diseases not provided for elsewhere

Abstract

The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis.

Claims

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

a nucleotide sequence encoding the polypeptide shown in FIG. 2 (SEQ ID NO;

2), FIG. 4 (SEQ ID NO;

4), FIG. 6 (SEQ ID NO;

6), FIG. 8 (SEQ ID NO;

8), FIG. 10 (SEQ ID NO;

10), FIG. 12 (SEQ ID NO;

12), FIG. 14 (SEQ ID NO;

14), FIG. 16 (SEQ ID NO;

16), FIG. 18 (SEQ ID NO;

18), FIG. 20 (SEQ ID NO;

20), FIG. 22 (SEQ ID NO;

22), FIG. 24 (SEQ ID NO;

24), FIG. 26 (SEQ ID NO;

26), FIG. 28 (SEQ ID NO;

28), FIG. 30 (SEQ ID NO;

30), FIG. 32 (SEQ ID NO;

32), FIG. 34 (SEQ ID NO;

34), FIG. 36 (SEQ ID NO;

36), FIG. 38 (SEQ ID NO;

38), FIG. 40 (SEQ ID NO;

40), or FIG. 42 (SEQ ID NO;

42).

5. A vector comprising the nucleic acid of claim 1.

6. The vector of claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of claim 5.

8. The host cell of claim 7, wherein said cell is a CHO cell, an E. coli cell or a yeast cell.

9. A process for producing a PRO polypeptide comprising culturing the host cell of claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:

1), FIG. 3 (SEQ ID NO;

3), FIG. 5 (SEQ ID NO;

5), FIG. 7 (SEQ ID NO;

7), FIG. 9 (SEQ ID NO;

9), FIG. 11 (SEQ ID NO;

11), FIG. 13 (SEQ ID NO;

13), FIG. 15 (SEQ ID NO;

15), FIG. 17 (SEQ ID NO;

17), FIG. 19 (SEQ ID NO;

19), FIG. 21A-B (SEQ ID NO;

21), FIG. 23 (SEQ ID NO;

23), FIG. 25 (SEQ ID NO;

25), FIG. 27 (SEQ ID NO;

27), FIG. 29 (SEQ ID NO;

29), FIG. 31 (SEQ ID NO;

31), FIG. 33 (SEQ ID NO;

33), FIG. 35 (SEQ ID NO;

35), FIG. 37 (SEQ ID NO;

37), FIG. 39 (SEQ ID NO;

39) and FIG. 41 (SEQ ID NO;

41).

3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:

1), FIG. 3 (SEQ ID NO;

3), FIG. 5 (SEQ ID NO;

5), FIG. 7 (SEQ ID NO;

7), FIG. 9 (SEQ ID NO;

9), FIG. 11 (SEQ ID NO;

11), FIG. 13 (SEQ ID NO;

13), FIG. 15 (SEQ ID NO;

15), FIG. 17 (SEQ ID NO;

17), FIG. 19 (SEQ ID NO;

19), FIG. 21A-B (SEQ ID NO;

21), FIG. 23 (SEQ ID NO;

23), FIG. 25 (SEQ ID NO;

25), FIG. 27 (SEQ ID NO;

27), FIG. 29 (SEQ ID NO;

29), FIG. 31 (SEQ ID NO;

31), FIG. 33 (SEQ ID NO;

33), FIG. 35 (SEQ ID NO;

35), FIG. 37 (SEQ ID NO;

37), FIG. 39 (SEQ ID NO;

39) and FIG. 41 (SEQ ID NO;

41).

10. An isolated polypeptide having at least 80% amino acid sequence identity to:

an amino acid sequence of the polypeptide shown in FIG. 2 (SEQ ID NO;

2), FIG. 4 (SEQ ID NO;

4), FIG. 6 (SEQ ID NO;

6), FIG. 8 (SEQ ID NO;

8), FIG. 10 (SEQ ID NO;

10), FIG. 12 (SEQ ID NO;

12), FIG. 14 (SEQ ID NO;

14), FIG. 16 (SEQ ID NO;

16), FIG. 18 (SEQ ID NO;

18), FIG. 20 (SEQ ID NO;

20), FIG. 22 (SEQ ID NO;

22), FIG. 24 (SEQ ID NO;

24), FIG. 26 (SEQ ID NO;

26), FIG. 28 (SEQ ID NO;

28), FIG. 30 (SEQ ID NO;

30), FIG. 32 (SEQ ID NO;

32), FIG. 34 (SEQ ID NO;

34), FIG. 36 (SEQ ID NO;

36), FIG. 38 (SEQ ID NO;

38), FIG. 40 (SEQ ID NO;

40), or FIG. 42 (SEQ ID NO;

42).

11. A chimeric molecule comprising a polypeptide according to claim 10 fused to a heterologous amino acid sequence.

12. The chimeric molecule of claim 11, wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.

13. An antibody which specifically binds to a polypeptide according to claim 10.

14. The antibody of claim 13, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

15. A composition of matter comprising (a) a polypeptide of claim 10, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, in combination with a carrier.

16. The composition of matter of claim 15, wherein said carrier is a pharmaceutically acceptable carrier.

17. The composition of matter of claim 16 comprising a therapeutically effective amount of (a), (b), (c) or (d).

18. An article of manufacture, comprising:

a container;

a label on said container; and

a composition of matter comprising (a) a polypeptide of claim 10, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said container, wherein label on said container indicates that said composition of matter can be used for treating psoriasis.

19. A method of treating psoriasis in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of (a) a polypeptide of claim 10, (b) an antagonist of said polypeptide, or (c) an antibody that binds to said polypeptide.

20. A method for determining the presence of a PRO polypeptide in a sample suspected of containing said polypeptide, said method comprising exposing said sample to an anti-PRO19597, anti-PRO83469, anti-PRO1189, anti-PRO83470, anti-PRO28700, anti-PRO1246, anti-PRO83471, anti-PRO6244, anti-PRO83472, anti-PRO19600, anti-PRO4977, anti-PRO83473, anti-PRO83474, anti-PRO617, anti-PRO71057, anti-PRO83475, anti-PRO1065, anti-PRO83476, anti-PRO200, anti-PRO1361 or anti-PRO83477 antibody and determining binding of said antibody to a component of said sample.

21. A method of diagnosing psoriasis in a mammal, said method comprising detecting the level of expression of a gene encoding PRO19597, PRO83469, PRO1189, PRO83470, PRO28700, PRO1246, PRO83471, PRO6244, PRO83472, PRO19600, PRO4977, PRO83473, PRO83474, PRO617, PRO71057, PRO83475, PRO1065, PRO83476, PRO200, PRO1361 or PRO83477 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of psoriasis in the mammal from which the test tissue cells were obtained.

22. A method of diagnosing an psoriasis in a mammal, said method comprising (a) contacting an anti-PRO19597, anti-PRO83469, anti-PRO1189, anti-PRO83470, anti-PRO28700, anti-PRO1246, anti-PRO83471, anti-PRO6244, anti-PRO83472, anti-PRO19600, anti-PRO4977, anti-PRO83473, anti-PRO83474, anti-PRO617, anti-PRO71057, anti-PRO83475, anti-PRO1065, anti-PRO83476, anti-PRO200, anti-PRO1361 or anti-PRO83477 antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of psoriasis in the mammal from which the test tissue cells were obtained.

23. A method of identifying a compound that inhibits the activity of PRO19597, PRO83469, PRO1189, PRO83470, PRO28700, PRO1246, PRO83471, PRO6244, PRO83472, PRO19600, PRO4977, PRO83473, PRO83474, PRO617, PRO71057, PRO83475, PRO1065, PRO83476, PRO200, PRO1361 or PRO83477 polypeptide, said method comprising contacting cells which normally respond to said polypeptide with (a) said polypeptide and (b) a candidate compound, and determining the lack responsiveness by said cell to (a).

24. A method of identifying a compound that inhibits the expression of a gene encoding a PRO19597, PRO83469, PRO1189, PRO83470, PRO28700, PRO1246, PRO83471, PRO6244, PRO83472, PRO19600, PRO4977, PRO83473, PRO83474, PRO617, PRO71057, PRO83475, PRO1065, PRO83476, PRO200, PRO1361 or PRO83477 polypeptide, said method comprising contacting cells which normally express said polypeptide with a candidate compound, and determining the lack of expression said gene.

25. The method of claim 24, wherein said candidate compound is an antisense nucleic acid.

26. A method of identifying a compound that mimics the activity of a PRO19597, PRO83469, PRO1189, PRO83470, PRO28700, PRO1246, PRO83471, PRO6244, PRO83472, PRO19600, PRO4977, PRO83473, PRO83474, PRO617, PRO71057, PRO83475, PRO1065, PRO83476, PRO200, PRO1361 or PRO83477 polypeptide, said method comprising contacting cells which normally respond to said polypeptide with a candidate compound, and determining the responsiveness by said cell to said candidate compound.